CTLA4 and metastatic melanoma: Tremelimumab (CP-675,206; AstraZeneca), another human IgG2 mAb to CTLA-4, has demonstrated some success in Phase I and II clinical trials for metastatic melanoma, but in 2008, it was terminated in Phase III trials due to treatment failure [289].